At AlphaNa, we are committed to integrating novel and emerging technologies across diverse discovery platforms and modalities.
AlphaNa adopts a disease-centered approach. We identify and establish the optimal technology platforms and modalities tailored to our desired target, indication, and patient population to ensure efficacy, safety, and druggability of candidate therapies.

TALENT^® (Therapeutic and Adaptive Lymphocyte Engineering & Navigation Technology) is AlphaNa’s proprietary core technology platform, designed with multi-layered innovation and modular integration. By combining in vivo immune cell programming (Engineering) with advanced nano-delivery technologies (Navigation / Nanoplatforms), TALENT^® establishes a system for precise immune modulation in vivo. Leveraging proprietary nano-delivery technologies, the platform enables efficient and targeted delivery of mRNA-based programming instructions to immune cells in vivo, thereby activating anti-infectious, anti-tumor, and immunoregulatory functions. Characterized by “High targeting precision, Robust immune activation, and tunable control”, the TALENT^® platform demonstrates the potential for systemic breakthroughs across in vivo CAR-T, immunotherapy, and infectious disease prevention.